



2019 NOMINEE BIOSKETCH FORM

NAME	Philip S. Boonstra
PRESENT POSITION	Research Assistant Professor, University of Michigan, USA
DEGREES	PhD, MS, Biostatistics, University of Michigan, Ann Arbor, Michigan, USA BA, Maths & Political Science, Calvin College, Grand Rapids, Michigan, USA
MAIN RESEARCH INTERESTS	<ol style="list-style-type: none"> 1. Data Integration 2. Early Phase Oncology Trial Methodology 3. Bayesian Shrinkage Priors 4. Penalized Likelihood
SELECTED PUBLICATIONS IN CLINICAL BIOSTATISTICS (LIMIT TO 5)	<ol style="list-style-type: none"> 1. Boonstra PS and Barbaro RP (2018). "Incorporating historical models with adaptive Bayesian updates." <i>Biostatistics</i>, doi:10.1093/biostatistics/kxy053 2. Boonstra PS, Braun TM, and others (2017). "Building the bridge to phase II: Efficacy estimation in dose-expansion cohorts." <i>Annals of Oncology</i> 28, 1427-1435 3. Boonstra PS*, Polk A*, and others (2017). "A Single Center Phase II Study of Ixazomib in Patients with Relapsed or Refractory Cutaneous or Peripheral T-cell Lymphomas" <i>American Journal of Hematology</i> 92, 1287-1294. 4. Boonstra PS, Shen JC, and others (2015). "A statistical evaluation of dose expansion cohorts in phase I clinical trials." <i>Journal of the National Cancer Institute</i> 107, dju429. 5. Boonstra PS, Mukherjee B, and Taylor JMG (2015). "A small-sample choice of the tuning parameter in ridge regression." <i>Statistica Sinica</i> 25, 1185-1206.
PAST AND CURRENT PARTICIPATION IN ISCB ACTIVITIES	Member of ISCB since 2013 Attended and presented at annual meetings of ISCB in 2013 (Munich), 2015 (Utrecht), and 2017 (Vigo).
GOALS AND VISION FOR THE ISCB	<p>I am a relatively junior member of the ISCB, having joined upon registering for my first annual meeting in Munich just five years ago. Even so, I am struck by the collegiality of the society, the quality of the scholarship presented at the annual meetings, a desire to make all types of biomedical research higher quality, and ongoing efforts of its leadership to be a truly international society. The society is egalitarian: opportunities for students abound, there are initiatives to encourage participation from the scientific communities of developing countries, and new members are welcomed at meetings just as enthusiastically as long-time members. As a member of ExCom, I will continue to advocate for and promote these virtues that I have seen the leadership so committed to already.</p> <p>As for outward-facing virtues, the STRATOS initiative, which has its origins in the ISCB, is a tangible example of how our society's members contribute to and serve the broader biomedical research community, and it demonstrates our field's commitment to being more than an academic clique. As one example of possible future directions: in the same way as STRATOS is serving the field of observational clinical research, I believe that an analogous initiative focusing on controlled, experimental clinical studies would be similarly welcomed. In summary, I will pursue ideas, initiatives, and directions that will both foster collaboration <i>within</i> our community and encourage service <i>beyond</i> our academic borders.</p>